Frovatriptan succinate hydrate (Frova) is effective in treating the full spectrum of migraine including the associated symptoms of nausea, vomiting, photophobia, and phonophobia. Frovatriptan succinate hydrate can also be used as in mini-prophylaxis in menstrual migraine. Frovatriptan succinate hydrate is a potent, high affinity, selective and orally active 5-HT1B, HT1D receptor agonist and a moderately potent 5-HT7 receptor agonist, with pKi values of 8.6, 8.4, and 6.7, respectively.

Frovatriptan is a highly potent agonist of the 5-HT 1B//D receptors, exhibiting the highest potency among triptan compounds. It possesses prominent cerebroselectivity. Frovatriptan demonstrates efficacy and even superiority in certain endpoints, including when administered during the headache phase of migraine attacks accompanied by aura [1].

Frovatriptan Succinate is a synthetic triptan with 5-HT1B/1D receptors agonist activity. It is indicated for the acute treatment of migraine.